Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The therapeutic landscape of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has evolved considerably following the approval of rituximab (RTX) and, more recently, the introduction of avacopan. These advances have diversified remission induction strategies. However, their impact on real-world clinical practice and outcomes remains uncertain. This study aimed to evaluate temporal changes in induction therapy patterns and to assess short-term renal and survival outcomes, as well as safety outcomes, before and after the introduction of RTX at our institution.
We conducted a single-center retrospective observational study, including patients hospitalized with newly diagnosed AAV between 2005 and 2024. Patients were classified into two cohorts based on the timing of admission: before (pre-2013) and after (post-2013) the approval of RTX in Japan. Patients with eosinophilic granulomatosis with polyangiitis (EGPA), positive anti–glomerular basement membrane (GBM) antibodies, a history of immunosuppressive therapy for other diseases, or insufficient follow-up (<6 months) were excluded. Clinical characteristics, induction regimens, and outcomes were compared between the two groups. The primary endpoint was a composite outcome of all-cause mortality or initiation of renal replacement therapy (RRT) within 6 months after induction. Secondary endpoints included severe infections requiring treatment and relapse of AAV within 6 months.
A total of 59 patients were analyzed (pre-approval group, n=16; post-approval group, n=43). Baseline demographics and kidney function were comparable between groups. Following the introduction of RTX and avacopan, the diversity of combination therapies increased. The use of steroid pulse therapy became significantly more frequent, whereas the initial and 2-month doses of oral prednisolone did not differ significantly between groups. The rates of mortality and RRT initiation within 6 months showed a downward trend but did not reach statistical significance. The incidence of severe infections requiring treatment was comparable between groups.
After the approval of RTX and the introduction of avacopan, remission induction strategies for AAV have diversified, enabling more individualized treatment based on patient background and disease severity. However, no significant improvement was observed in short-term renal or survival outcomes or in infection risk. These findings suggest that further optimization of treatment regimens, particularly with respect to minimizing glucocorticoid exposure, remains warranted.
